


# Supplementary Figure 1



Speculative schema of the mechanism of evolocumab-dependent platelet destruction through immune mechanisms. PCSK9-evolocumab complex containing IgG interacting with the platelet Fc receptors (A) and evolocumab-platelet membrane complex harboring neoantigenic determinants where excess evolocumab attaches onto the platelet membrane (B). In the former case, IgG directed against the PCSK9-evolocumab complex as the antigen was generated, and the complex bound to the platelet Fc receptor through the antibodies. PAIgG, platelet-associated immunoglobulin G.